Despite Constrained Reimbursement of Drugs and Tight Pricing Controls, the Colorectal Cancer and Prostate Cancer Markets i

A Shift to Higher-Priced Agents Will Contribute to Growth in the CRC Market, While the Launch of New Agents and Changes in Medical Practice Will be Key Drivers of CaP Market Expansion, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that while reimbursement constraints and tightening control of drug prices restrict the revenue potential of branded products in the colorectal cancer (CRC) and prostate cancer (CaP) markets in Brazil, the region presents an attractive commercial opportunity for companies targeting these indications. Decision Resources forecasts the CRC market in Brazil will grow from $453 million in 2010 to $621 million in 2015, a compound annual growth rate (CAGR) of 6.5 percent. Over the same time period, Brazil’s CaP market is expected to grow from $336 million to $418 million over the same time period, a CAGR of 4.5 percent.

Market growth for both indications will be driven in part by a growing pool of drug-treated CRC and CaP patients. Additionally, in the CRC market, a shift to higher-priced chemotherapy and targeted agents will contribute to its growth. According to the findings, surveyed Brazilian oncologists report greater use of targeted add-on treatments and novel chemotherapies, including increased use of Roche’s Xeloda in both locally advanced and metastatic CRC.

Meanwhile, in the CaP market, the launch of new agents will be a key driver of anticipated growth. Several novel premium-priced agents will launch before 2015, including Johnson & Johnson’s Zytiga, Amgen/GlaxoSmithKline/Daiichi Sankyo’s Prolia/Xgeva, AstraZeneca’s zibotentan and Medivation/Astellas’ MDV-3100. Decision Resources forecasts emerging CaP therapies will earn combined sales of $43 million in 2015—ten percent of the CaP market.

Changes in medical practice will also be a driver of CaP market growth.

“Chemotherapy currently sees little use in nonmetastatic CaP patients, both in Brazil and the major markets. However, it is expected that, by 2015, chemotherapy will be used more for CaP in Brazil, not only across all lines of treatment for metastatic patients but also in the earlier stages of the disease,” said Decision Resources Analyst Natalia Reoutova, M.A., M.Sc. “Recent approval of Sanofi’s Jevtana in Brazil will lead to an increasing number of patients being re-treated with chemotherapy after first-line failure of docetaxel (Sanofi’s Taxotere, generics) or mitoxantrone, providing an alternative to docetaxel for metastatic patients in second and third lines of treatment and significantly increasing sales in these populations.”

These findings are included in two new reports, Colorectal Cancer in Brazil and Prostate Cancer in Brazil, both of which feature extensive primary research with Brazilian medical oncologists as well as a market outlook through 2015.

Webinar

Clients who purchase the findings included in this press release will be eligible to attend an upcoming webinar on June 23, 2011 entitled Current and Future Use of Western Brands in Brazil’s Oncology Market: Spotlight on Colorectal and Prostate Cancer. Members of the media are welcome to attend this webinar; for more information, please contact Lisa Osgood at [email protected].

About Emerging Markets Reports

Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  Brazil  North America  South America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Mental Health  Oncology  Pharmaceutical  Other Health  General Health

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.